Patterns of medication use and imaging following initial diagnosis of sarcoidosis
Copyright © 2021 Elsevier Ltd. All rights reserved..
INTRODUCTION: Sarcoidosis is a rare inflammatory disease with unclear natural history. Using a large, retrospective, longitudinal, population-based cohort, we sought to define its natural history in order to guide future clinical studies.
METHODS: We identified 722 newly diagnosed cases of sarcoidosis within Kaiser Permanente Northwest health care records between 1995 and 2015. We investigated immunosuppressive medication use in the two years following diagnosis, analyzed demographic and clinical characteristics, and quantified chest imaging and pulmonary function testing (PFTs) across the clinical course.
RESULTS: Over two years of follow-up, 41% of patients were treated with prednisone. Of those, 75% tapered off their first course within 100 days, although half of those patients required recurrent therapy. Five percent of the entire cohort remained on prednisone for longer than one year, with an average daily dose of 10-20 mg. Chest imaging was associated with early prednisone use, and chest CT was associated with changes in prednisone dose. PFTs or demographics were not associated with prednisone use. Cumulative prednisone doses were significantly higher in African Americans (1,845 mg additional) and those who had a chest CT (2,015 mg additional). Overall, PFTs were less frequently obtained than chest imaging and had no significant change over disease course.
DISCUSSION: The natural history of sarcoidosis varies greatly. For those requiring therapy, corticosteroid burden is high. Chest imaging drives medication dose changes as compared to PFTs, but neither outcome fully captures the entire history of disease. Prospective cohorts are needed with purposefully collected, repeated measures that include objective clinical assessments and symptoms.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:189 |
---|---|
Enthalten in: |
Respiratory medicine - 189(2021) vom: 28. Nov., Seite 106622 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Simmering, J [VerfasserIn] |
---|
Links: |
---|
Themen: |
Chest imaging |
---|
Anmerkungen: |
Date Completed 07.02.2022 Date Revised 08.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.rmed.2021.106622 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM331414724 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM331414724 | ||
003 | DE-627 | ||
005 | 20240308231855.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.rmed.2021.106622 |2 doi | |
028 | 5 | 2 | |a pubmed24n1320.xml |
035 | |a (DE-627)NLM331414724 | ||
035 | |a (NLM)34600163 | ||
035 | |a (PII)S0954-6111(21)00330-9 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Simmering, J |e verfasserin |4 aut | |
245 | 1 | 0 | |a Patterns of medication use and imaging following initial diagnosis of sarcoidosis |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.02.2022 | ||
500 | |a Date Revised 08.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
520 | |a INTRODUCTION: Sarcoidosis is a rare inflammatory disease with unclear natural history. Using a large, retrospective, longitudinal, population-based cohort, we sought to define its natural history in order to guide future clinical studies | ||
520 | |a METHODS: We identified 722 newly diagnosed cases of sarcoidosis within Kaiser Permanente Northwest health care records between 1995 and 2015. We investigated immunosuppressive medication use in the two years following diagnosis, analyzed demographic and clinical characteristics, and quantified chest imaging and pulmonary function testing (PFTs) across the clinical course | ||
520 | |a RESULTS: Over two years of follow-up, 41% of patients were treated with prednisone. Of those, 75% tapered off their first course within 100 days, although half of those patients required recurrent therapy. Five percent of the entire cohort remained on prednisone for longer than one year, with an average daily dose of 10-20 mg. Chest imaging was associated with early prednisone use, and chest CT was associated with changes in prednisone dose. PFTs or demographics were not associated with prednisone use. Cumulative prednisone doses were significantly higher in African Americans (1,845 mg additional) and those who had a chest CT (2,015 mg additional). Overall, PFTs were less frequently obtained than chest imaging and had no significant change over disease course | ||
520 | |a DISCUSSION: The natural history of sarcoidosis varies greatly. For those requiring therapy, corticosteroid burden is high. Chest imaging drives medication dose changes as compared to PFTs, but neither outcome fully captures the entire history of disease. Prospective cohorts are needed with purposefully collected, repeated measures that include objective clinical assessments and symptoms | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
650 | 4 | |a Chest imaging | |
650 | 4 | |a Clinical endpoints | |
650 | 4 | |a Corticosteroids | |
650 | 4 | |a Natural history | |
650 | 4 | |a Sarcoidosis | |
650 | 7 | |a Glucocorticoids |2 NLM | |
650 | 7 | |a Immunosuppressive Agents |2 NLM | |
650 | 7 | |a Prednisone |2 NLM | |
650 | 7 | |a VB0R961HZT |2 NLM | |
700 | 1 | |a Stapleton, E M |e verfasserin |4 aut | |
700 | 1 | |a Polgreen, P M |e verfasserin |4 aut | |
700 | 1 | |a Kuntz, J |e verfasserin |4 aut | |
700 | 1 | |a Gerke, A K |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Respiratory medicine |d 1993 |g 189(2021) vom: 28. Nov., Seite 106622 |w (DE-627)NLM012605247 |x 1532-3064 |7 nnns |
773 | 1 | 8 | |g volume:189 |g year:2021 |g day:28 |g month:11 |g pages:106622 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmed.2021.106622 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 189 |j 2021 |b 28 |c 11 |h 106622 |